In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.

In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson &amp; Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.

Pharmaceutical Executive Daily: FDA's Approval of Epkinly

<div>The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. </div>

Science

Life Sciences

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com" rel="noopener noreferrer">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.&nbsp;

Share Pharmaceutical Executive Daily: FDA's Approval of Epkinly

Sign up to save your podcasts

Pharmaceutical Executive Daily: FDA's Approval of Epkinly

Pharmaceutical Executive Daily: FDA's Approval of Epkinly

More shows like Pharmaceutical Executive

Global News Podcast

WSJ Your Money Briefing

WSJ What’s News

The McKinsey Podcast

WSJ Tech News Briefing

HBR IdeaCast

WSJ Minute Briefing

Bold Names

The Readout Loud

Thoughts on the Market

The Journal.

BioCentury This Week

Biotech Hangout

The So What from BCG

WSJ's Take On the Week